Photodynamic therapy agent with a built-in apoptosis sensor for evaluating its own therapeutic outcome in situ

Area of Science:

• Oncology
• Biochemistry
• Medical Imaging

Background:

• Real-time assessment of apoptosis post-cancer therapy is crucial for evaluating treatment efficacy.
• Photodynamic therapy (PDT) is an effective cancer treatment modality.
• Current methods for apoptosis detection can be time-consuming and lack real-time imaging capabilities.

Purpose of the Study:

• To develop a single-agent system that combines photodynamic therapy with in situ apoptosis imaging.
• To create a tool for real-time monitoring of therapeutic outcomes in cancer treatment.

Main Methods:

• Development of a "photodynamic therapy agent with a built-in apoptosis sensor" (PDT-BIAS).
• PDT-BIAS incorporates a fluorescent photosensitizer linked to a quencher via a caspase-3 cleavable peptide.
• In vitro experiments utilizing cancer cells, Apoptag, and MTT assays to validate functionality.

Main Results:

• Cleavage of the peptide linker by caspase-3 upon apoptosis induction resulted in a measurable increase in fluorescence.
• PDT-BIAS successfully induced and imaged apoptosis in cancer cells following PDT treatment.
• Apoptosis involvement and drug efficacy were confirmed by complementary assays.

Conclusions:

• PDT-BIAS effectively combines cancer therapy and apoptosis imaging in a single agent.
• This novel agent enables real-time, in situ monitoring of apoptosis, facilitating prompt assessment of therapeutic response.
• PDT-BIAS holds promise for improving cancer treatment monitoring and personalized medicine approaches.